Nov 20, 2017

PHI and Germany’s federal institute for materials research pursue joint patent application

Phase Holographic Imaging (PHI) and Germany’s federal institute for materials research (BAM) has agreed to jointly enter the national phase of international patent application “Molecularly Imprinted Polymers” in Europe, USA, China and Japan. An international patent application is a preliminary review prior to national applications. Patents are only granted nationally.

PHI has obtained a 75 % ownership of the invention by compensating three of the inventors for accrued expenses. In the event of successful commer­cial­ization, the inventors will be further compensated by PHI according to the Swedish Act on Rights to Inventions made by Employees. BAM retains its 25 % ownership of the invention.

Scientists have extensively searched for a biomarker which at an early stage uniquely identifies cancer, without success. However, new research show that a combination of biomarkers are uniquely present in cancer cells. The invention relates to the nanoparticles which are used and developed in the GlycoImaging project to identify these biomarkers. GlycoImaging is a EU funded collaboration between PHI, BAM, Malmö University, University of Copenhagen, University of Turku and Umeå University, aiming to develop improved cancer diagnostic applications based on PHI’s holographic microscopy technology and molecularly imprinted nanoparticles, also known as synthetic plastic antibodies.

[ EU grants 2.1 million euro to Phase Holographic Imaging and Malmö University with partners for joint cancer research]

About BAM

The Bundesanstalt für Materialforschung und -prüfung (BAM) is a non-commercial senior scientific and technical federal institute with responsibility to Germany’s Federal Ministry for Economic Affairs and Energy. The particular remit of BAM is to advance safety in technology and chemistry, to test materials and systems (thereby analyzing the test results based on the applied principles of physics and chemistry and providing reference methods and reference materials), to promote the transfer of knowledge and technology in its key fields of research, to collaborate on the development of statutory regulations (e.g. safety standards and threshold limits) and to advise the German government, industry, national and international organizations on materials science and chemistry.

The above information was made public pursuant to the EU Market Abuse Regulation.

Sep 25, 2017

PHI Launches Wound Healing Assay

PHI today launches the HoloMonitor® Wound Healing Assay. The assay meets the unmet market demand of both quantifying cell movement automatically and in great detail. Wound healing assays are one of the most used laboratory methods to study cell movement. Conventional wound healing assays are either manual or just measure the collective movement of a cell population.

Image sequence of a “wound” closure

About Wound Healing Assays

By creating a “wound” in cultured cells, wound healing assays mimic the cell movement in living organisms. The method is, however, manual and labor intensive, especially when measuring the movement of individual cells. In preclinical research, this often results in that individual cell movement is ignored; even though individual cell movement is of crucial importance in the formation of meta­stasis, for example. With the HoloMonitor Wound Healing Assay, cell movement is rapidly quantified both on a population level and on an individual cell level, characterized by:

  • Cell friendly — label-free
  • User friendly — set-up and walk away
  • Automatic quantification of “wound” closure
  • Quantification of individual cell movement by cell tracking

For further information, please visit:

www.phiab.se/applications/wound-healing

Jul 18, 2017

Options exercised IV

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget. The options are market valued according to Black & Scholes. After recalculation with reference to equity issues, option program 2012 qualifies for subscription of 43 872 shares at 16.50 SEK per share (originally 40 000 shares at 18.12 SEK) per share and option program 2013 for subscription of 209 000 shares at 12.80 SEK per share (originally 190 000 shares at 14.00 SEK per share). The number of registered shares in PHI was 11 576 939 on June 30, 2017.

Board members Leland Foster and Bengt Falk have now requested to exercise their entire option holdings. Hereby Foster subscribes for 10 766 shares in option program 2012 and 44 000 shares in option program 2013. Falk subscribes for 22 000 shares in option program 2013. The 76 766 shares subscribed by Foster and Falk will increase the equity of PHI by 1 022 439 SEK. Foster finances his subscription and associated taxes by divesting some of his current holdings. Currently, Falk has no stock holdings in PHI.

Previously, Klas Cramborn (chairman of the board), Jan Richardsson (board member), Ron Lowy (advisor) and a former board member have exercised their entire option holdings.

The above information was made public pursuant to the EU Market Abuse Regulation.

Jul 14, 2017

Options exercised III

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget. The options are market valued according to Black & Scholes. After recalculation with reference to equity issues, option program 2012 qualifies for subscription of 43 872 shares at 16.50 SEK per share (originally 40 000 shares at 18.12 SEK) per share and option program 2013 for subscription of 209 000 shares at 12.80 SEK per share (originally 190 000 shares at 14.00 SEK per share). The number of registered shares in PHI was 11 576 939 on June 30, 2017.

Advisor Ron Lowy has now requested to exercise his entire option holdings. Hereby Lowy subscribes for 10 766 shares in option program 2012 and 44 000 shares in option program 2013, in total 54 766 shares. Lowy finances his subscription and associated taxes by divesting some of his current holdings. Through Lowy’s subscriptions, the equity of PHI will in-crease by 740 839 SEK.

Previously, Klas Cramborn (chairman of the board), Jan Richardsson (board member) and a former board member have exercised their entire option holdings.

The above information was made public pursuant to the EU Market Abuse Regulation.

Jun 13, 2017

Leading Australian research institute purchase HoloMonitor

A first HoloMonitor was recently deployed at QIMR Berghofer Medical Research Institute in Brisbane Australia. With the purchase, the institute upgrades its quantitative time-lapse cytometry capacity to also include instrumentation for measuring the behavior of individual cells in a cell population, without requiring the cells to be labeled with toxic chemicals or through genetic manipulation. The customer list price of the delivered HoloMonitor system amounts to €37 500.

HoloMonitor in operation at QIMR Berghofer

“Label-free cytometers based on conven­tional microscopy, marketed by Essen BioScience and others, are limited to measuring the bottom area covered by a cell population. This installation is special in that HoloMonitor expands and refines QIMR Berghofer’s current time-lapse capabilities to include label-free cell population analysis on an individual cell level — a new capability that medical science just has begun to explore”, said Peter Egelberg, CEO and founder of PHI.

QIMR Berghofer is home to more than 900* scientists, students and support staff. It is one of Australia’s most successful medical research institutes. The institute was established in 1945 by the Queensland Government and has a rich history of scientific discoveries and applied medical research.
*According to recent information provided by QIMR

The above information was made public pursuant to the EU Market Abuse Regulation.

May 11, 2017

Options exercised II

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget. The options are market valued according to Black & Scholes. After recalculation with reference to equity issues, option program 2012 qualified for subscription of 43 872 shares at 16.50 SEK per share (originally 40 000 shares at 18.12 SEK) per share and option program 2013 for subscription of 209 000 shares at 12.80 SEK per share (originally 190 000 shares at 14.00 SEK per share). Since a previous board member in March this year exercised all his options, re-maining options enabled subscription of 225 388 shares.

The Board chairman Klas Cramborn and the Board member Jan Richardsson have now requested exercise of their entire option holdings. Hereby Cramborn subscribes for 10 766 shares in option program 2012 och 44 000 shares in option program 2013, totally 54 766 shares. Richardsson subscribes for 11 000 shares in option program 2013.

Through these subscriptions, the equity of PHI increases by 881 639 SEK. The exercise of the options implies a dilution of 0.6 % for current shareholders. After registration of the new shares at Bolagsverket (Swedish Companies Registration Office), the total number of shares in PHI will amount to 11 642 705 and the share capital to 2 328 541 SEK.

To finance his subscription, Cramborn has sold 40 000 shares during the period May 8-10, 2017. After the exercise of his options, Cramborn´s holding will be 64 776 shares, an increase by 14 766 shares.

Richardsson`s holding (private and via company) will amount to 41 802 shares, an increase by 11 000 shares, after the exercise of his options.

After the transactions, remaining options will enable subscription of 159 622 shares, implying a dilution of 1.6 % for current shareholders.

The above information was made public pursuant to the EU Market Abuse Regulation.

Mar 21, 2017

Options exercised I

PHI has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget. The options are market valued according to Black & Scholes. After recalculation with reference to equity issues, option program 2012 qualifies for sub­scrip­tion of 43 872 shares at 16.50 SEK per share (originally 40 000 shares at 18.12 SEK) per share and option program 2013 for subscription of 209 000 shares at 12.80 SEK per share (originally 190 000 shares at 14.00 SEK per share). If all 252 872 shares are subscribed, the share capital of the Company will increase by 50 574 SEK (2.14 % dilution) and the equity by 3 399 088 SEK.

Ulf Avrin, board member of PHI until October 2014, has now exercised his entire option holdings, subscribing 5 484 shares at 16.50 SEK per share and 22 000 shares at 12.80 SEK per share. Through this subscription, the equity of PHI increases by 372 086 SEK. The exercise of the options implies a dilution of 0.2 % for current shareholders. After registration of the new shares at Bolagsverket (Swedish Companies Registration Office), the total number of shares in PHI will amount to 11 576 939 and the share capital to 2 315 387.80 SEK.

The above information was made public pursuant to the EU Market Abuse Regulation.

Mar 20, 2017

PHI and Malmö University receives 2.3 million kronor to detect blood-borne cancer cells

PHI and a group of experts associated with Malmö University was recently awarded a 2.3 million kronor grant by the Knowledge Foundation (KK-stiftelsen, Sweden). In close collaboration with GlycoImaging, the funded project aim to develop new methods for detecting blood-borne metastatic cancer cells.

There are today no simple methods to detect cancer – with a blood test, for example. In most cases, cancer is therefore first diagnosed when a patient consults a doctor because of the symptom the cancer develops. Sadly, this all too often results in that the cancer is treated when it is too late. Before symptoms develop, cancer cells are however often released in the blood stream. Improved detection methods of blood-borne cancer cells would make it possible to diagnose aggressive and intractable cancer with a routine blood test, before symptoms develop.

GlycoImaging is a collaboration project between PHI, Malmö University and four international research institutions. By combining PHI’s HoloMonitor technology with a new type of cancer probes, GlycoImaging aim to develop more sensitive methods to detect and diagnose cancer at an earlier stage than what is possible today. GlycoImaging is funded by a previous grant of €2.1 million from the European Commission.

“The long-term goal is to develop new and improved clinical methods to diagnose cancer. However, the same methods can readily be used in a preclinical context. The projects therefore also provide expertise and resources to in the near-term improve and expand our current HoloMonitor product line, targeting the preclinical research market”, said CEO Peter Egelberg.

To allow commercialization of the developed methods and their substantial market potential, PHI has the right to freely acquire or license the intellectual property rights which emerge in the projects.

The above information was made public pursuant to the EU Market Abuse Regulation.

Mar 2, 2017

Novel HoloMonitor-based research to be presented at cancer research annual meeting

The research results by three research groups at Northeastern University and Lund University will be presented at the American Association for Cancer Research Annual Meeting in April. Using HoloMonitor® technology from PHI the scientists have been able to follow and measure important dynamics of cancer cells in ways not possible with conventional methods, which has led to the novel research results. The presentations will be held in connection to PHI’s exhibit at the meeting. For additional information regarding the presentations see here.

Jan 3, 2017

Japan's foremost medical institute purchases multiple HoloMonitor instruments

Japan's foremost medical research institute, The Institute of Medical Science at University of Tokyo, recently purchased two HoloMonitor M4.5 instruments for a total list price of €75 000, excluding discount. Together with RIKEN and Kyoto University, the institute spearheads Japan’s national effort to become the undisputed leader of regenerative medicine in the world.

Stem cells transform into specialized cells through a series of trans­formations. The image show how blood stem cells develop into various types of blood cells.

All specialized cells in our bodies (e.g. muscle, blood and brain cells) originate from stem cells. Stem cells are unspecialized cells that under certain conditions transform into tissue- or organ-specific cells. Regenerative medicine aims to control and harness the power of stem cells to repair or replace diseased cells, tissues and organs. Cell therapies and regenerative medicine promise to treat and cure some of the most devastating and costly diseases in the world today.

Conventional drug development uses cultured cells to test a new drug before it is tested on humans. Regenerative medicine is radically different in that the cells themselves are the treatment. Traditional methods are ill-suited to study stem cells as they require the cells to be stained. The toxicity of these stains alters cell behavior and make transplantation impossible. HoloMonitor allows scientists to study how stem cells develop into specialized cells without using these toxic stains.

Articles about regenerative medicine in Japan and at University of Tokyo

The above information was made public pursuant to the EU Market Abuse Regulation.